9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced setting.

Trial Details

NCT ID
NCT06823427
Phase
PHASE2
Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • 9MW2821
  • Toripalimab (JS001 )
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Voluntary participation
  • Histologically confirmed inoperable locally advanced or metastatic urothelial carcinoma (including bladder, renal pelvis and ureter). Mixed histolo…
  • Has not received any systemic treatment for locally advanced or metastatic urothelial carcinoma
  • At least 1 measurable target lesion that satisfies RECIST v1.1 definition. If the patient has received radiotherapy, the target lesion needs to be …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →